Apples And Oranges? Not All PI3 Kinase Inhibitors Are Created Equal
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
As development and deal-making activity in the phosphatidyinositol-3-kinase (PI3 kinase) area increases, a crucial question has emerged. Will early investments in pan-selective PI3 kinase inhibitors pay off, or will the more recent focus on isoform-selective compounds prove the better approach to this space?
You may also be interested in...
Ahead of ASCO, Exelixis Inks Lucrative Deal With Sanofi For Its PI3 Kinase Inhibitors
Exelixis cashes in on a hot therapeutic drug target, showing that an R&D-focused biotech can succeed in the marketplace.
Roche Acquires Genentech Oncology Partner Piramed
$175 million deal nets Roche a novel program of signal transduction inhibitors with utility in cancer and inflammatory disease.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011